1. Home
  2. KYMR vs LCII Comparison

KYMR vs LCII Comparison

Compare KYMR & LCII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KYMR
  • LCII
  • Stock Information
  • Founded
  • KYMR 2015
  • LCII 1956
  • Country
  • KYMR United States
  • LCII United States
  • Employees
  • KYMR N/A
  • LCII N/A
  • Industry
  • KYMR Medicinal Chemicals and Botanical Products
  • LCII Auto Parts:O.E.M.
  • Sector
  • KYMR Health Care
  • LCII Consumer Discretionary
  • Exchange
  • KYMR Nasdaq
  • LCII Nasdaq
  • Market Cap
  • KYMR 3.0B
  • LCII 2.8B
  • IPO Year
  • KYMR 2020
  • LCII N/A
  • Fundamental
  • Price
  • KYMR $42.30
  • LCII $110.63
  • Analyst Decision
  • KYMR Buy
  • LCII Hold
  • Analyst Count
  • KYMR 16
  • LCII 6
  • Target Price
  • KYMR $54.00
  • LCII $112.20
  • AVG Volume (30 Days)
  • KYMR 456.9K
  • LCII 210.7K
  • Earning Date
  • KYMR 10-31-2024
  • LCII 02-11-2025
  • Dividend Yield
  • KYMR N/A
  • LCII 3.87%
  • EPS Growth
  • KYMR N/A
  • LCII 164.26
  • EPS
  • KYMR N/A
  • LCII 5.13
  • Revenue
  • KYMR $87,563,000.00
  • LCII $3,775,614,000.00
  • Revenue This Year
  • KYMR N/A
  • LCII $1.09
  • Revenue Next Year
  • KYMR $33.16
  • LCII $4.36
  • P/E Ratio
  • KYMR N/A
  • LCII $21.78
  • Revenue Growth
  • KYMR 86.92
  • LCII N/A
  • 52 Week Low
  • KYMR $22.35
  • LCII $96.19
  • 52 Week High
  • KYMR $53.27
  • LCII $131.36
  • Technical
  • Relative Strength Index (RSI)
  • KYMR 41.34
  • LCII 38.74
  • Support Level
  • KYMR $40.95
  • LCII $110.53
  • Resistance Level
  • KYMR $44.17
  • LCII $120.58
  • Average True Range (ATR)
  • KYMR 2.32
  • LCII 2.91
  • MACD
  • KYMR -0.33
  • LCII -0.90
  • Stochastic Oscillator
  • KYMR 16.07
  • LCII 13.21

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

About LCII LCI Industries

LCI Industries Inc supplies domestically and internationally components for the original equipment manufacturers of recreational vehicles and adjacent industries including buses; and trailers used to haul boats, livestock, equipment, and other cargo. It has two reportable segments; the original equipment manufacturers segment and the aftermarket segment. The OEM Segment manufactures or distributes components for the OEMs of RVs and adjacent industries, including buses; trailers used to haul boats, livestock, equipment, and other cargo; trucks; pontoon boats; trains; manufactured homes; and modular housing. Its products are sold primarily to major manufacturers of RVs such as Thor Industries, Forest River, Winnebago, and other RV OEMs, and to manufacturers in adjacent industries.

Share on Social Networks: